Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.Peer-Reviewed Original ResearchSafety run-inProgression free survivalHigh-risk smoldering myelomaSmoldering multiple myelomaSmoldering myelomaMultiple myelomaRun-inHigh-risk smoldering multiple myelomaRisk of progression to myelomaNo dose limiting toxicitiesRate of tumor regressionProgression to myelomaRecurrent grade 3Treatment of intermediate-Grade 3 thrombocytopeniaCycles of therapyDose-limiting toxicityMedian patient ageOverall survival benefitStem cell collectionToxic therapeutic optionsRisk stratification modelTreatment of intermediateRelapsed myelomaCryptococcal meningitis